Billion kronor investment in next generation biologics
Minister for Enterprise and Innovation Mikael Damberg and Minister for Higher Education and Research Helene Hellmark Knutsson presented a national programme for protein research, method development and biologics production.
The research programme, which aims to make Sweden a leader in the development and production of biologics, will be established at VINNOVA, the Swedish Agency for Innovation Systems, which will run the programme in close collaboration with the Swedish Research Council. The research programme will extend over a period of eight years and state funding will total SEK 320 million.
The research programme is part of the Government's strategic investment in the life sciences that aims to improve health, meet societal challenges and strengthen Sweden's competitiveness in an international context.
"Sweden has a strong base in biologics production and we have a proud tradition of protein research that we want to build on. The research programme will strengthen Sweden's competitiveness in an international context," says Mr Damberg.
"Strategic and long-term investments in life sciences research are key to discovering and producing new medicines. In the long run, it is crucial for our well-being and for improving human health," says Ms Hellmark Knutsson.
"Collaboration between academia and industry, and between small and large companies, is essential to managing health-related societal challenges. Life sciences are a priority of the Prime Minister's Innovation Council and as such have the Government's full attention," says Mr Damberg, who like Ms Hellmark Knutsson, is a member of the Innovation Council.
"The Government is taking steps to strengthen Swedish research and innovation. This investment in next generation biologics is part of efforts to make Sweden a leading research nation. Sweden will not settle for less," says Ms Hellmark Knutsson.
The Government is presenting the initiative jointly with the Knut and Alice Wallenberg Foundation and AstraZeneca. At the same time, AstraZeneca will present its research collaboration on proteins and biologics.